Becton Dickinson and Company BDX

$183.83 +0.01 (0.01%)

Valuation

Market cap
50,649,764,000
Revenue TTM
$21,840,000,000
Net income TTM
$1,678,000,000
PE ratio
13.79
Forward PE
14.15
Profit margin
7.68%
Debt to equity
0.55

Trading

Volume
1,885,600
Avg volume
1,806,490
Day's range
$181.95 – $184.34
Shares out
275,540,000
Stochastic %K
71%
Beta
0.21
Analysts
Sell
Price target
$190.47

Price

Company profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peri...

Show more

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Industry
Medical Instruments & Supplies
Sector
Healthcare
Phone
201 847 6800
Website
https://www.bd.com
Address
1 Becton Drive, Franklin Lakes, United States

Latest news

Stocktwits

BioTechHealthX Sep 26, 1:04 PM
$BDX BD says Fairview Health Services is deploying its Vmax 160 pharmacy robot. Here’s what the rollout means for its automation business—and why BDX is a broader bet. https://biotechhealthx.com/biotech-news/becton-dickinson-bdxs-pharmacy-robot-just-got-a-real-world-test-is-this-a-great-investment-opportunity/
0 replies
BioTechHealthX Sep 25, 7:28 AM
$ARAY $SSII $BDX $GMED $JNJ Surgical robots get the headlines, but pharmacy automation and robotic cancer treatment belong in the conversation too. See which 10 stocks made the best medical stocks ranking. https://biotechhealthx.com/biotech-news/top-10-medical-robotics-stocks-to-buy-today/
0 replies
Inphatec Sep 15, 5:45 PM 0 replies
abishop717 Sep 15, 1:43 PM 0 replies
spql8r Aug 25, 6:27 PM
$AMFN During my working years with $LH and $DGX, we deal with companies like $BDX and $DHR, which have a ton of patents. I remember LabCorp one day when it was looking to buy a lab in Tustin, CA. When I researched the lab, it did not have much volume. What's interesting is it has a lot of patents. The big 2 labs usually buy the lab because they have the volume, because volume equals revenue. So patents are important. AMFN is preparing for the future with revenues from the patents or exclusivity. In the lab business, they usually pay 5x the revenue. I know, it's less than the multiplier in other fields since it's 10 to 30 times more. What we have here—commercialization of Texatron, a fusion engine soon to power up data centers—is unique. Rarity also has a multiplier. Take a look, NFA. DYODD.😎 5737👀
0 replies
CapitalMonk Aug 22, 2:07 AM
$BDX Price: $192.00 (+2.33%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.59% RSI: 85.3 | Momentum: Moderate Volume: -7.2% vs avg Volatility: 1.72% Support: $157.09 | Resistance: $192.29 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 replies
Stocktwits52wHighs Aug 21, 5:31 PM
$BDX printed a new 52-week high today
0 replies
ZacharyBrooks497 Aug 20, 7:35 AM
$LHX $CBRS $DEO $BDX $STT L3Harris benefits from defense and aerospace spending, CBRS remains speculative, Diageo benefits from global beverage demand, Becton Dickinson benefits from medical-device and healthcare demand, and State Street benefits from asset servicing and investment activity. I'm watching defense contracts, liquidity, consumer volumes, procedure demand, and asset flows.
0 replies